JP7577819B2 - Ａｈｒアゴニスト - Google Patents

Ａｈｒアゴニスト Download PDF

Info

Publication number
JP7577819B2
JP7577819B2 JP2023194117A JP2023194117A JP7577819B2 JP 7577819 B2 JP7577819 B2 JP 7577819B2 JP 2023194117 A JP2023194117 A JP 2023194117A JP 2023194117 A JP2023194117 A JP 2023194117A JP 7577819 B2 JP7577819 B2 JP 7577819B2
Authority
JP
Japan
Prior art keywords
compound
mixture
pharma
formula
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023194117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024072283A5 (https=
JP2024072283A (ja
Inventor
グレゴリー ベル，マイケル
アン カーソン，シェリル
ショヴィニエ－ハインズ，ラシー
アレクサンダー クラーク，クリスチャン
リン ガーナート，ダグラス
ジェイムズ グリーン，スティーブン
トーマス マクミレン，ウィリアム
チャールズ ドーシー，フランク
ナバルロ，アントニオ
ロバート リッゾ，ジョン
ロバート カルヴィン，ジョエル
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2024072283A publication Critical patent/JP2024072283A/ja
Publication of JP2024072283A5 publication Critical patent/JP2024072283A5/ja
Priority to JP2024186560A priority Critical patent/JP2025032072A/ja
Application granted granted Critical
Publication of JP7577819B2 publication Critical patent/JP7577819B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023194117A 2022-11-15 2023-11-15 Ａｈｒアゴニスト Active JP7577819B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024186560A JP2025032072A (ja) 2022-11-15 2024-10-23 Ａｈｒアゴニスト

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263425442P 2022-11-15 2022-11-15
US63/425,442 2022-11-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024186560A Division JP2025032072A (ja) 2022-11-15 2024-10-23 Ａｈｒアゴニスト

Publications (3)

Publication Number Publication Date
JP2024072283A JP2024072283A (ja) 2024-05-27
JP2024072283A5 JP2024072283A5 (https=) 2024-10-21
JP7577819B2 true JP7577819B2 (ja) 2024-11-05

Family

ID=89121650

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023194117A Active JP7577819B2 (ja) 2022-11-15 2023-11-15 Ａｈｒアゴニスト
JP2024186560A Pending JP2025032072A (ja) 2022-11-15 2024-10-23 Ａｈｒアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024186560A Pending JP2025032072A (ja) 2022-11-15 2024-10-23 Ａｈｒアゴニスト

Country Status (17)

Country Link
US (1) US20240199608A1 (https=)
EP (1) EP4619401A1 (https=)
JP (2) JP7577819B2 (https=)
KR (1) KR20250083557A (https=)
CN (1) CN120225518A (https=)
AR (1) AR131070A1 (https=)
AU (1) AU2023382389A1 (https=)
CL (1) CL2025001421A1 (https=)
CO (1) CO2025005456A2 (https=)
CR (1) CR20250175A (https=)
DO (1) DOP2025000111A (https=)
IL (1) IL320832A (https=)
JO (1) JOP20250109A1 (https=)
MX (1) MX2025005566A (https=)
PE (1) PE20251588A1 (https=)
TW (2) TW202523664A (https=)
WO (1) WO2024107555A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240124A1 (en) * 2024-05-14 2025-11-20 Eli Lilly And Company Processes for preparing enantiomeric compounds and related molecules
CN120904199B (zh) * 2025-09-30 2026-03-06 上海泽德曼医药科技有限公司 具有稠环结构的化合物及其在医药上的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492364B1 (en) 1998-12-04 2002-12-10 Toray Industries, Inc. Triazolo and derivatives as chemokine inhibitors
JP2006504658A (ja) 2002-07-25 2006-02-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用
WO2007074491A1 (en) 2005-12-28 2007-07-05 Universita Degli Studi Di Siena HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
WO2011054843A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Bromodomain inhibitors for treating autoimmune and inflammatory diseases
JP2012229239A (ja) 2004-05-28 2012-11-22 Janssen Pharmaceutica Nv 薬剤耐性マイコバクテリア性疾患の処置のための置換キノリン誘導体の使用
WO2018171602A1 (zh) 2017-03-21 2018-09-27 正大天晴药业集团股份有限公司 用于ido和tdo双重抑制剂的脲类化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2510528A1 (de) * 1975-03-11 1976-09-23 Hoechst Ag Benzimidazo-/1,2-a/-chinoline und verfahren zu ihrer herstellung
NL7709746A (nl) * 1976-09-09 1978-03-13 Hoechst Ag Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
AU2004220176A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
JP2007506788A (ja) * 2003-09-26 2007-03-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｈｃｖ感染阻害剤とその使用法
WO2008014307A2 (en) 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
US12312337B2 (en) * 2019-05-10 2025-05-27 Antidote Ip Holdings, Llc Compounds and methods for treating cancer
AR126963A1 (es) * 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492364B1 (en) 1998-12-04 2002-12-10 Toray Industries, Inc. Triazolo and derivatives as chemokine inhibitors
JP2006504658A (ja) 2002-07-25 2006-02-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用
JP2012229239A (ja) 2004-05-28 2012-11-22 Janssen Pharmaceutica Nv 薬剤耐性マイコバクテリア性疾患の処置のための置換キノリン誘導体の使用
WO2007074491A1 (en) 2005-12-28 2007-07-05 Universita Degli Studi Di Siena HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
WO2011054843A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Bromodomain inhibitors for treating autoimmune and inflammatory diseases
WO2018171602A1 (zh) 2017-03-21 2018-09-27 正大天晴药业集团股份有限公司 用于ido和tdo双重抑制剂的脲类化合物

Also Published As

Publication number Publication date
PE20251588A1 (es) 2025-06-16
KR20250083557A (ko) 2025-06-10
TW202523664A (zh) 2025-06-16
AR131070A1 (es) 2025-02-12
IL320832A (en) 2025-07-01
US20240199608A1 (en) 2024-06-20
JP2025032072A (ja) 2025-03-11
TW202434583A (zh) 2024-09-01
JOP20250109A1 (ar) 2025-05-13
WO2024107555A1 (en) 2024-05-23
CL2025001421A1 (es) 2025-08-18
DOP2025000111A (es) 2025-06-15
EP4619401A1 (en) 2025-09-24
AU2023382389A1 (en) 2025-05-15
CN120225518A (zh) 2025-06-27
JP2024072283A (ja) 2024-05-27
CO2025005456A2 (es) 2025-05-19
CR20250175A (es) 2025-05-27
TWI870104B (zh) 2025-01-11
MX2025005566A (es) 2025-06-02

Similar Documents

Publication Publication Date Title
JP6873980B2 (ja) ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
KR101686685B1 (ko) 피라졸로피리미딘 ｊａｋ 억제제 화합물 및 방법
JP2022506887A (ja) 窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用
JP2025522631A (ja) Ｐｒｍｔ５阻害剤及びその使用
US9688654B2 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP7577819B2 (ja) Ａｈｒアゴニスト
US20080125588A1 (en) SYNTHESIS OF 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3-d] PRYIMIDIN-7-ONES
JP2021510151A (ja) アルツハイマー病等のタウ凝集体に関連する障害の治療、緩和、または予防のための１，３，４，５−テトラヒドロ−２ｈ−ピリド（４，３−ｂ）インドール誘導体
SG184874A1 (en) Compounds and methods for kinase modulation, and indications therefor
BG65106B1 (bg) Заместени 2-арил-3-(хетероарил)-имидазо[1,2-а]пиримидини, лекарствени средства, които ги съдържат, използването им и метод за тяхното получаване
JP2002105085A (ja) 新規イミダゾチアゾール誘導体
JP2021525272A (ja) タウ凝集体に関連する障害の治療、緩和、または予防のためのテトラヒドロベンゾフロ［２，３−ｃ］ピリジンおよびベータ−カルボリン化合物
KR20170129810A (ko) 치환된 트리시클릭 헤테로시클릭 화합물
JP2025500886A (ja) 大環状ｂｔｋ阻害剤
JP6526064B2 (ja) ピリドピリミジンジオン誘導体
JP7523480B2 (ja) ヒドラゾンアミド誘導体及びその抗骨粗鬆症薬の調製における応用
EP4103279B1 (en) Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
WO2023098857A1 (zh) Irak4抑制剂及其用途
JP2024501281A (ja) Ｉｒａｋ４阻害剤としての２ｈ－インダゾール誘導体及び疾患の治療におけるそれらの使用
US6833374B2 (en) Dihydropyrazolo[3,4-d]thieno[2,3-B]pyridinone inhibitors of B7-1
WO2025191115A1 (en) Trem2 modulators
JP2010534231A (ja) デュシェンヌ型筋ジストロフィーを治療するための化合物
CN121941683A (zh) 含氮并环类化合物、其药物组合物及其应用
CN118215655A (zh) Ahr激动剂
CA3212872A1 (en) Indoline derivatives as ddrs inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231220

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241010

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241023

R150 Certificate of patent or registration of utility model

Ref document number: 7577819

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150